Experienced interventional radiologists to provide medical and technical
advice to treatment users
OTTAWA, June 5, 2012 /CNW/ - Nordion Inc. (TSX: NDN) (NYSE: NDZ), a
leading provider of products and services for the prevention, diagnosis
and treatment of disease, today announced the launch of a new preceptor
program to support doctors using TheraSphere®, the company's Yttrium-90 (Y-90) glass microsphere liver cancer treatment.
Matthew Johnson, MD, Professor of Radiology and Surgery at the Indiana
University School of Medicine in Indianapolis, and Siddharth Padia, MD,
Assistant Professor of Interventional Radiology at the University of
Washington in Seattle, are both highly experienced TheraSphere® users, having between them administered more than 1,000 Y-90
radioembolization treatments. As preceptors, they will help guide and
coach physicians at various stages of TheraSphere® clinical use.
"Nordion wants to help physicians develop a solid technical foundation
for treating hepatocellular carcinoma with TheraSphere®," explained Mason Ross, MD, Nordion's VP of Medical Affairs. "This
program is designed to assist doctors to make independent decisions
with confidence about the use and administration of TheraSphere®. With the training programs at our Centers of Excellence in the US and
Europe, our technical proctors and these new physician preceptors,
Nordion now offers end-to-end training and support for physicians in
the use of Therasphere®, whether it's their first dose or their 100th."
The preceptors will provide medical and technical advice to physicians
using TheraSphere®. Their role includes:
Advising peers on appropriate patient selection and screening
Reviewing imaging scans of potential patients
Providing guidance on treatment planning
Reviewing dosimetry and dose selection considerations for specific
Advising on treatment administration techniques
Providing post-treatment guidance
"Because the availability of Y-90 therapy is relatively recent, it's
critical for physicians to be able to leverage and share experience and
best practices," said Dr. Johnson. "I'm pleased that Nordion has
recognized this and is establishing this forum."
The preceptors will be available by email and are committed to providing
timely responses to questions from physicians.
"We will be helping our peers troubleshoot in real time, perfect their
skills and expand their knowledge," added Dr. Padia. "Learning is a
continuous process and I believe everyone involved in these
consultations will benefit from them."
TheraSphere® is a liver cancer therapy that consists of millions of small glass
beads (20 to 30 micrometers in diameter) containing radioactive Y-90.
The product is injected by physicians into the artery of the patient's
liver through a catheter, which allows the treatment to be delivered
directly to the tumour via blood flow.
In the US, TheraSphere® is used to treat patients with hepatocellular carcinoma (HCC) who can
have appropriately positioned hepatic arterial catheters, and can be
used as a bridge to surgery or transplantation in these patients. It
is also indicated for the treatment of HCC patients with partial or
branch portal vein thrombosis or occlusion when clinical evaluation
warrants the treatment. TheraSphere® is approved by the U.S. Food and Drug Administration (FDA) under a
Humanitarian Device Exemption (HDE). HDE approvals are based on
demonstrated safety and probable clinical benefit. However,
effectiveness of the indication for use has not been established.
Common side effects include mild to moderate fatigue, pain and nausea
for about a week. Physicians describe these symptoms as similar to
those of the flu. Some patients experience some loss of appetite and
temporary changes in several blood tests. For details on rare or more
severe side effects, please refer to the TheraSphere® package insert/instructions for use at www.nordion.com/therasphere.
About Nordion Inc.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company
that provides market-leading products used for the prevention,
diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries
around the world. Our products are used daily by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals,
clinics and research laboratories. Nordion has more than 500 highly
skilled employees in three locations. Find out more at www.nordion.com and follow us at http://twitter.com/NordionInc.
SOURCE Nordion Inc.
For further information:
(613) 592-3400 x. 2414
Cell: (613) 291-3689